comScore (NASDAQ:SCOR) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.
Insider and Institutional Ownership
72.1% of comScore shares are held by institutional investors. Comparatively, 62.4% of OptimizeRx shares are held by institutional investors. 2.5% of comScore shares are held by insiders. Comparatively, 8.1% of OptimizeRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares comScore and OptimizeRx's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
comScore | -15.53% | -20.81% | -7.34% |
OptimizeRx | -16.20% | -10.86% | -8.66% |
Analyst Ratings
This is a breakdown of recent recommendations for comScore and OptimizeRx, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
comScore | 0 | 0 | 2 | 0 | 3.00 |
OptimizeRx | 0 | 0 | 4 | 0 | 3.00 |
comScore currently has a consensus target price of $5.00, indicating a potential upside of 50.60%. OptimizeRx has a consensus target price of $69.75, indicating a potential upside of 38.94%. Given comScore's higher probable upside, analysts plainly believe comScore is more favorable than OptimizeRx.
Risk & Volatility
comScore has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.
Earnings & Valuation
This table compares comScore and OptimizeRx's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
comScore | $388.64 million | 0.65 | $-339,000,000.00 | ($5.33) | -0.62 |
OptimizeRx | $24.60 million | 34.30 | $-3,140,000.00 | ($0.19) | -264.21 |
OptimizeRx has lower revenue, but higher earnings than comScore. OptimizeRx is trading at a lower price-to-earnings ratio than comScore, indicating that it is currently the more affordable of the two stocks.
Summary
comScore beats OptimizeRx on 7 of the 13 factors compared between the two stocks.